Mississauga, ON -- (SBWIRE) -- 09/09/2013 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Adamis Pharmaceuticals Announces Positive Results with HSV Therapy.”
Companies mentioned in this article include Adamis Pharmaceuticals Corp. (OTCQB:ADMP), 3M Company (NYSE:MMM) and GlaxoSmithKline (NYSE:GSK).
It’s not exactly popular to talk about, but herpes simplex viruses, or HSV, affect billions of people across the globe. In fact, it’s estimated that up to one-third of the world’s population, or about 2.3 billion people, suffer from various forms of chronic HSV infections. Zooming in to a more specific indication, it’s estimated that the global incidence rate of ocular keratitis, an HSV eye infection, is approximately 1.5 million new cases annually. Ocular keratitis can cause a cornea infection and is the most common cause of cornea-derived blindness, with about 40,000 of those new cases including severe vision impairment or blindness each year.
Adamis Pharmaceuticals Corp. (OTCQB:ADMP), a commercial-stage, San Diego-based specialty pharmaceutical company focused on a wide range of diseases and conditions, is aiming to provide relief for HSV conditions with its antimicrobial and spermicidal agent, called C31G. Through two divisions, the company has a large pipeline of pharmaceuticals in development from early to late stages, including a New Drug Application with the Food and Drug Administration for epinephrine pre-filled syringes for allergic emergencies. Three other drugs, for asthma/chronic obstructive pulmonary disease (COPD) and allergic rhinitis, are entering Phase III clinical trials, according to the company’s website.
The full version of this article can be found at:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)